2Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med, 2000,6 ( 12 ) : 1399-1402.
3Massy ZA, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation : effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun,2000,267 (2) :536-540.
4Heusinger RJ, Fischer B, Goppelt SM, et al. Differential effects of simvastatin on mesangial cells. Kidney Int, 2004, 66( 1 ) : 187-195.
5Bussolati B, Deregibus MC, Fonsato V, et al. Statins prevent ox-idized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol3-kinase/AKT-signaling pathway. J Am Soc Nephrol, 2005,16(7) : 1936-1947.
6Vieira JM Jr, Rodrigues LT, Mantovani E, et al. Statin monotherapy attenuates renal injury in a salt-sensitive hypertension model of renal disease. Nephron Physiol, 2005, 101(4) :82-91.
7Vasantha K, Lixia Z, Hui P, et al Targeting of RhoA/ ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes, 2008, 57 (3) :714-723.
8Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-3- methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial ceils via modulation of Rho GTPase p21 signaling pathway: implications for diabetic nephropathy. PNAS,2002,99(12) :8301-8305.
9Singh R, Alavi N, Singh AK, et al. Role of angiotensin II in glucose- induced inhibition of mesangial matrix degradation. Diabetes, 1999,48 (10) :2066-2073.
10Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high glucose and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol,2006,291 ( 1 ) :F116-F121.
